Company Overview We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune T cell activator and Versamune in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune T cell-activator in infectious diseases. We believe our investigational targeted immunotherapies have the potential to overcome limitations of current im...
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-30 | 2025-12-31 | 0001140361-26-012030 | EDGAR | 101K words |
| 2025-03-27 | 2024-12-31 | 0001140361-25-010717 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001140361-24-016265 | EDGAR | — |
| 2023-03-28 | 2022-12-31 | 0001140361-23-014279 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001140361-22-012244 | EDGAR | — |
| 2021-03-18 | 2020-12-31 | 0001140361-21-009142 | EDGAR | — |
| 2020-03-27 | 2019-12-31 | 0001140361-20-007252 | EDGAR | — |
| 2019-02-21 | 2018-12-31 | 0001140361-19-003636 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001140361-18-011218 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001140361-17-010287 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001140361-25-041976 | EDGAR | 26K words |
| 2025-08-13 | 2025-06-30 | 0001140361-25-030825 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001140361-25-018967 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001140361-24-046891 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001140361-24-037067 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001140361-24-026295 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001140361-23-053242 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001140361-23-039544 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001140361-23-024692 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001140361-22-041370 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001140361-22-028567 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0001140361-22-018571 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001140361-26-011862 | EDGAR | 2K words |
| 2026-03-03 | 0001140361-26-007478 | EDGAR | — |
| 2026-02-23 | 0001140361-26-006410 | EDGAR | — |
| 2026-02-20 | 0001140361-26-006229 | EDGAR | — |
| 2026-01-28 | 0001140361-26-002608 | EDGAR | — |
| 2026-01-22 | 0001140361-26-001958 | EDGAR | — |
| 2026-01-09 | 0001140361-26-000786 | EDGAR | — |
| 2025-12-09 | 0001140361-25-044940 | EDGAR | — |
| 2025-12-02 | 0001140361-25-043889 | EDGAR | — |
| 2025-11-13 | 0001140361-25-041805 | EDGAR | — |
337 total filings indexed. 305 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001472091 |
| Ticker | PDSB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pdsbiotech.com |
| Listed | 2015-10-01 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report